<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2225">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269034</url>
  </required_header>
  <id_info>
    <org_study_id>2010-435</org_study_id>
    <secondary_id>3R01DK077166-05S1</secondary_id>
    <nct_id>NCT01269034</nct_id>
  </id_info>
  <brief_title>New Onset Type 1 Diabetes: Role of Exenatide</brief_title>
  <official_title>New Onset Type 1 Diabetes: Role of Exenatide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are many recent advances in insulin treatment of type 1 diabetes, however after a meal&#xD;
      sugars are always a concern. There is a drug Exenatide (Byetta) which is FDA approved to&#xD;
      treat people with type 2 diabetes which helps correct their glucoses (sugars) after meals.&#xD;
      This study is going to test whether this drug can improve the after meal sugars in people&#xD;
      with new onset type 1 diabetes. To test this you will be given a dose of exenatide (1.25 mcg)&#xD;
      and long acting insulin or inulin alone before the boost. There is also a placebo group&#xD;
      (healthy subjects) who do not get any medication before the boost. Insulin levels and other&#xD;
      hormones that affect blood glucose as well as your sugar will be measured by a series of&#xD;
      blood tests. The role exenatide as compared to insulin alone will be examined to prevent low&#xD;
      blood sugars which might occur because of food staying longer in the stomach than usual or&#xD;
      due to the suppression of a hormone called glucagon which increases blood sugar. If you&#xD;
      qualify you will be given exenatide (Byetta 1.25 mcg) along with insulin or insulin alone.&#xD;
      You and the researchers will not know which dose you are taking at any single visit. A total&#xD;
      of 20 people in which some will be children aged 12- 18 years will participate, being&#xD;
      diagnosed within 3 months of having been found to have type 1 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of this study are to determine the following:&#xD;
&#xD;
        1. The role of exenatide as compared to insulin monotherapy in reducing postprandial&#xD;
           hyperglycemia.&#xD;
&#xD;
        2. The role of exenatide on postprandial glucagon and gastric emptying.&#xD;
&#xD;
        3. The effect of long acting insulin on postprandial glucose excursions, glucagon&#xD;
           concentrations and gastric emptying.&#xD;
&#xD;
        4. Postprandial glucose excursions, glucagon concentrations and gastric emptying in normal&#xD;
           healthy controls.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      A randomized, non-blinded trial with a crossover design will be used. Following informed&#xD;
      consent and with appropriate subject assent, all subjects will have a screening visit.&#xD;
      Following the screening visit, subjects with T1DM will undergo 3 studies: Part A (exenatide&#xD;
      and long acting insulin), Part B (rapid and long acting insulin) and Part C (long acting&#xD;
      insulin only). The subjects will be admitted to the CRC on three separate occasions, at least&#xD;
      3-4 weeks apart. The three studies will be performed in a random order and the randomization&#xD;
      will be done using a computerized system. The healthy controls will undergo a single study&#xD;
      visit. Except for the absence of diabetes, the healthy controls will be identical to the&#xD;
      study subjects. Subjects with new onset diabetes will be compared to healthy controls.&#xD;
&#xD;
      During the study, if blood glucose values in a subject are less than 55 mg/dl, IV glucose of&#xD;
      5-15 grams will be administered to achieve euglycemia (90-130 mg/dl). 1-2 doses of IV glucose&#xD;
      should correct hypoglycemia. If more than 3 doses are required to achieve euglycemia, the&#xD;
      study will be terminated, the subject will be offered a meal tray and blood sugar rechecked&#xD;
      to ensure euglycemia. If blood sugar at any time is more than 350 with moderate ketones, the&#xD;
      study will be terminated.&#xD;
&#xD;
      At around 1 PM (270 min), lunch will be provided (consistent carbohydrate meal) and insulin&#xD;
      will be given as per the subject's prescribed regimen. The subject will be discharged home&#xD;
      with a designated driver due to the risk of hypoglycemia.&#xD;
&#xD;
      A subject will be withdrawn from participating in the study if he/she meets any of the&#xD;
      following conditions: 1)develops a chronic disease 2)develops anemia 3)becomes pregnant&#xD;
      4)develops a weight loss of greater than 10 pounds for unspecified reasons 5)loss of contact-&#xD;
      if the investigators are unable to reach a study subject (within 2 months of screening or&#xD;
      completion of the first study) by phone or mail to schedule the next appointment. All study&#xD;
      subjects (that are withdrawn from the study) will receive a phone call and a letter notifying&#xD;
      them that they have been withdrawn.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.</measure>
    <time_frame>February 2013</time_frame>
    <description>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Role of Exenatide on Postprandial Glucagon and Gastric Emptying.</measure>
    <time_frame>February 2013</time_frame>
    <description>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls.</measure>
    <time_frame>February 2013</time_frame>
    <description>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide and long acting insulin before the boost.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapid and long acting insulin before the boost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>healthy controls without any medication before the boost.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>1.25 mcg before the boost sub-cutaneously.</description>
    <arm_group_label>Part A</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapid and long acting insulin</intervention_name>
    <description>Depends on their Carbohydrate ratio and body needs</description>
    <arm_group_label>Part B</arm_group_label>
    <other_name>Novolog/ Humalog</other_name>
    <other_name>Lantus/ Levemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>long acting insulin + rapid acting + 1.25 mcg Exenatide</intervention_name>
    <description>Depends on their body needs.</description>
    <arm_group_label>Part C</arm_group_label>
    <other_name>Lantus</other_name>
    <other_name>Levemir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 12-18 years of age at the time of enrollment.&#xD;
&#xD;
          2. Diagnosed with antibody positive T1DM in the past 3 months.&#xD;
&#xD;
          3. Otherwise healthy except for their TIDM and treated hypothyroidism.&#xD;
&#xD;
          4. Females must have a negative pregnancy test.&#xD;
&#xD;
          5. Hemoglobin equal to or greater than 12 g/dl before each study.&#xD;
&#xD;
          6. Weight greater than 44 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any chronic disease: leukemia, inflammatory bowel disease, cystic fibrosis, juvenile&#xD;
             rheumatoid arthritis etc, except for diabetes and hypothyroidism.&#xD;
&#xD;
          2. Any medications that may affect glucose metabolism.&#xD;
&#xD;
          3. Abnormal AST, ALT, amylase, lipase, creatinine (more than 3 times normal values).&#xD;
&#xD;
          4. Lack of a supportive family environment as detected by the clinicians and/or social&#xD;
             workers.&#xD;
&#xD;
          5. History of substance abuse (evaluated by medical history and CRAFFT questionnaire&#xD;
             which will be administered at the screening visit).&#xD;
&#xD;
          6. Positive pregnancy test in females.&#xD;
&#xD;
          7. Lactating and nursing mothers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjitha Katikaneni, MB; BS</last_name>
    <role>Study Director</role>
    <affiliation>Montefiore Children's hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein CRC- West Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 29, 2010</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <results_first_submitted>September 11, 2020</results_first_submitted>
  <results_first_submitted_qc>July 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes Milletus</keyword>
  <keyword>diabetes</keyword>
  <keyword>healthy controls</keyword>
  <keyword>exenatide</keyword>
  <keyword>byetta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 27, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT01269034/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 13 people in which some will be children aged 12- 18 years will participate, being diagnosed within 3 months of having been found to have type 1 diabetes.</recruitment_details>
      <pre_assignment_details>&quot;Each participant only received one part (A,B, or C) and did not cross over to the subsequent parts</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A</title>
          <description>Exenatide and long acting insulin before the boost.&#xD;
Exenatide: 1.25 mcg before the boost sub-cutaneously.</description>
        </group>
        <group group_id="P2">
          <title>Part B</title>
          <description>Rapid and long acting insulin before the boost&#xD;
Rapid and long acting insulin: Depends on their Carbohydrate ratio and body needs</description>
        </group>
        <group group_id="P3">
          <title>Part C</title>
          <description>long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost&#xD;
long acting insulin + rapid acting + 1.25 mcg Exenatide: Depends on their body needs.</description>
        </group>
        <group group_id="P4">
          <title>Healthy Controls</title>
          <description>healthy controls without any medication before the boost.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A</title>
          <description>Exenatide and long acting insulin before the boost.&#xD;
Exenatide: 1.25 mcg before the boost sub-cutaneously.</description>
        </group>
        <group group_id="B2">
          <title>Part B</title>
          <description>Rapid and long acting insulin before the boost&#xD;
Rapid and long acting insulin: Depends on their Carbohydrate ratio and body needs</description>
        </group>
        <group group_id="B3">
          <title>Part C</title>
          <description>long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost&#xD;
long acting insulin + rapid acting + 1.25 mcg Exenatide: Depends on their body needs.</description>
        </group>
        <group group_id="B4">
          <title>Healthy Controls</title>
          <description>healthy controls without any medication before the boost.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.</title>
        <description>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</description>
        <time_frame>February 2013</time_frame>
        <population>The original PI and their entire team left the institution. Despite repeated efforts to contact the PI and study team members, the PI and study team members refused to disclose any collected data. Additionally, no secondary information sources such as study publications exist from which to summarize collected data</population>
        <group_list>
          <group group_id="O1">
            <title>Part A</title>
            <description>Exenatide and long acting insulin before the boost.&#xD;
Exenatide: 1.25 mcg before the boost sub-cutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Part B</title>
            <description>Rapid and long acting insulin before the boost&#xD;
Rapid and long acting insulin: Depends on their Carbohydrate ratio and body needs</description>
          </group>
          <group group_id="O3">
            <title>Part C</title>
            <description>long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost&#xD;
long acting insulin + rapid acting + 1.25 mcg Exenatide: Depends on their body needs.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls</title>
            <description>healthy controls without any medication before the boost.</description>
          </group>
        </group_list>
        <measure>
          <title>The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.</title>
          <description>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</description>
          <population>The original PI and their entire team left the institution. Despite repeated efforts to contact the PI and study team members, the PI and study team members refused to disclose any collected data. Additionally, no secondary information sources such as study publications exist from which to summarize collected data</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Role of Exenatide on Postprandial Glucagon and Gastric Emptying.</title>
        <description>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</description>
        <time_frame>February 2013</time_frame>
        <population>The original PI and their entire team left the institution. Despite repeated efforts to contact the PI and study team members, the PI and study team members refused to disclose any collected data. Additionally, no secondary information sources such as study publications exist from which to summarize collected data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A</title>
            <description>Exenatide and long acting insulin before the boost.&#xD;
Exenatide: 1.25 mcg before the boost sub-cutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Part B</title>
            <description>Rapid and long acting insulin before the boost&#xD;
Rapid and long acting insulin: Depends on their Carbohydrate ratio and body needs</description>
          </group>
          <group group_id="O3">
            <title>Part C</title>
            <description>long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost&#xD;
long acting insulin + rapid acting + 1.25 mcg Exenatide: Depends on their body needs.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls</title>
            <description>healthy controls without any medication before the boost.</description>
          </group>
        </group_list>
        <measure>
          <title>The Role of Exenatide on Postprandial Glucagon and Gastric Emptying.</title>
          <description>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</description>
          <population>The original PI and their entire team left the institution. Despite repeated efforts to contact the PI and study team members, the PI and study team members refused to disclose any collected data. Additionally, no secondary information sources such as study publications exist from which to summarize collected data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls.</title>
        <description>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</description>
        <time_frame>February 2013</time_frame>
        <population>The original PI and their entire team left the institution. Despite repeated efforts to contact the PI and study team members, the PI and study team members refused to disclose any collected data. Additionally, no secondary information sources such as study publications exist from which to summarize collected data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A</title>
            <description>Exenatide and long acting insulin before the boost.&#xD;
Exenatide: 1.25 mcg before the boost sub-cutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Part B</title>
            <description>Rapid and long acting insulin before the boost&#xD;
Rapid and long acting insulin: Depends on their Carbohydrate ratio and body needs</description>
          </group>
          <group group_id="O3">
            <title>Part C</title>
            <description>long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost&#xD;
long acting insulin + rapid acting + 1.25 mcg Exenatide: Depends on their body needs.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls</title>
            <description>healthy controls without any medication before the boost.</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls.</title>
          <description>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</description>
          <population>The original PI and their entire team left the institution. Despite repeated efforts to contact the PI and study team members, the PI and study team members refused to disclose any collected data. Additionally, no secondary information sources such as study publications exist from which to summarize collected data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years</time_frame>
      <desc>While Adverse Events were monitored/assessed, none were observed</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A</title>
          <description>Exenatide and long acting insulin before the boost.&#xD;
Exenatide: 1.25 mcg before the boost sub-cutaneously.</description>
        </group>
        <group group_id="E2">
          <title>Part B</title>
          <description>Rapid and long acting insulin before the boost&#xD;
Rapid and long acting insulin: Depends on their Carbohydrate ratio and body needs</description>
        </group>
        <group group_id="E3">
          <title>Part C</title>
          <description>long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost&#xD;
long acting insulin + rapid acting + 1.25 mcg Exenatide: Depends on their body needs.</description>
        </group>
        <group group_id="E4">
          <title>Healthy Controls</title>
          <description>healthy controls without any medication before the boost.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The original PI and their entire team has left the institution. Repeated attempts for complete data have gone unanswered. Outcome measure data is not available to provide full and complete results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Roger Hicks, Administrative Director for Research - Department of Pediatrics</name_or_title>
      <organization>Albert Einstein College of Medicine</organization>
      <phone>718-920-7386</phone>
      <email>roger.hicks@einsteinmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

